Published results have demonstrated an oncogenic role for Notch3 in preclinical T-ALL models and treatment efficacy for Notch-signaling inhibitors in T-ALL cell lines wild type for Notch1 but harboring Notch3 GOF mutations (Bellavia et al., 2000; Choi et al., 2017). The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.